US Stock Market Closed

Dashboard

Acorda Therapeutics, Inc. (ACOR)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

About

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include AMPYRA (dalfampridine), INBRIJA (levodopa inhalation powder), BTT1023 (timolumab), SYN120, rHIgM22, and GGF2 (Cimaglermin alfa). The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

CEO

Ronald Cohen

Employees

344

Industry

-

Sector

-

Headquarters

Ardsley

Exchange

NASDAQ

Summary Stats

Market Cap

7.49M

Revenue

123M

Net Income

-95M

EPS

-$8.22

Price-to-Earnings

-0.07

Price-to-Book

0.06

Debt-to-Equity

2.33

News

Analyst Ratings

Price targets projected by 3 analysts

High

$5.00

Average

$2.33

Low

$1.00

Ratings calculated by 3 analysts

Buy

1

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Not Available

Actual

-$1.66 -

Consensus

-

Report Date

Year Ago

-2.46

Year Ago Change %

Up 32%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites